In 172 fit adults with untreated AML (mostly adverse-risk; FLT3, CBF and younger NPM1 excluded), azacitidine-venetoclax gave longer median event-free survival than induction chemotherapy (14.5 vs 6.2 months; HR 0.57) in a phase 2 trial.
RCTn = 172
Fathi et al. Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia